Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
Thursday November 26 2009 | Biotechnology feed | All feeds
|
|
|
Ro 28-2653, an MMP inhibitor with anti-cancer activity The therapeutic efficacy of synthetic inhibitors of matrix-metalloproteinases (MMPs) in various cancers has been demonstrated. As a result Celltech in partnership with BMS have entered BMS-275291 into phase III clinical trials for the treatment of non-small cell lung cancer. A second molecule, Abbott's ABT-518 has recently entered the clinic. Most recently, Roche report on Ro 28-2653, a molecule with high affinity for MMP2, MMP9 and membrane type 1-MMP. Ro 28-2653 (10-300 mg/kg per day; po) was administered to rats with experimental prostate cancer, and was shown to reproducibly reduce tumor weight by up to 90% in a dose-dependent manner. This effect was observed whether treatment started soon after the inoculation with cancer cells or after tumors had become established. Ro 28-2653 treatment also significantly prolonged survival. More recently 2 publications have appeared reporting that Ro 28-2653 both impairs mitochondrial function and induces apoptosis in prostate cancer cells. The profile of Ro 28-2653 is thus particularly exciting and further development is eagerly awaited.
Adapted from Lein et al, Oncogene 2002 Mar 27;21(13):2089-96 Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
